Non-total body irradiation (TBI)-based conditioning in next-generation sequencing-minimal residual disease (NGS-MRD)-negative B acute lymphocytic leukemia (ALL) was associated with high event-free and overall survival after allogeneic hematopoietic cell transplantation (HCT). These outcomes were comparable to historical TBI-based approaches, while post-HCT NGS-MRD status was strongly correlated with relapse risk, supporting the use of molecularly guided conditioning strategies.

Findings from the FLAURA2 study reveal that combining osimertinib with platinum-pemetrexed significantly improves overall survival in patients with advanced EGFRm NSCLC, demonstrating clear benefits over monotherapy even in those with adverse baseline prognostic factors.

The ALEX study's final analysis shows that first-line alectinib significantly improves OS and duration of response in untreated advanced ALK+ NSCLC compared to crizotinib, reinforcing alectinib as the standard of care for these patients.

The monarchE trial reveals that adjuvant abemaciclib combined with endocrine therapy (ET) significantly enhances overall survival (OS) and invasive disease-free survival in patients with high-risk, hormone receptor-positive (HR+), HER2-negative early breast cancer, establishing this regimen as a new standard of care.

STUDY DESIGN Dostarlimab in conjunction with carboplatin-paclitaxel (CP) has previously been shown to significantly improve progression-free survival (PFS) and overall survival (OS) outcomes compared with CP alone in patients with primary advanced or recurrent endometrial cancer (EC).1 This has led

STUDY DESIGN Niraparib is a potent and highly selective poly-ADP ribose polymerase (PARP) inhibitor.1 PARP inhibitors have shown a trend of favorable overall survival (OS) in platinum-sensitive recurrent ovarian cancer (PSROC) in the maintenance setting.1 However, this OS benefit appears inconsiste

Thrombocytosis is frequently observed among cancer patients and can be attributed to increased platelet production.1 While the underlying pathophysiology has not been completely elucidated, it is believed that platelet activation is essential for tumor progression due to the release of several plate

STUDY DESIGN For over 2 decades, locally advanced cervical cancer (LACC) has been treated with external beam radiotherapy (EBRT) and concurrent chemotherapy, followed by brachytherapy.1 However, the toxicity associated with these treatments along with the burden of the disease itself have led to a

Progression-free survival (PFS) is often utilized as an indicator of the overall survival (OS) of patients with endometrial cancer (EC) to facilitate regulatory approval for novel medical treatments.1 Nevertheless, its role as a surrogate marker for the survival outcomes of EC patients remains contr

The updated results from the DESTINY-Breast03 phase 3 trial showed that trastuzumab deruxtecan significantly prolonged progression-free survival (PFS) and overall survival (OS) among patients with human epidermal growth factor receptor 2-positive (HER2-positive) unresectable and/or metastatic breast